title: Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
abstract: BACKGROUND
  CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy; NCT00635492) assessed, as its primary objective, the time to a 'significant treatment change' (defined within this paper) after patients with type 2 diabetes mellitus initiated their first injectable, glucose-lowering therapy [exenatide twice daily (BID) or insulin] in clinical practice in six European countries and evaluated outcomes during the study.
  
  
  METHODS
  CHOICE was a 24-month, prospective, noninterventional observational study. Patients were invited to participate in CHOICE only after their treating physician had made the clinical decision to initiate first injectable therapy with either exenatide BID or insulin. Clinical data were collected at initiation of first injectable therapy and after approximately 3, 6, 12, 18, and 24 months.
  
  
  RESULTS
  A total of 2,515 patients were recruited; 1,114 patients in the exenatide BID cohort and 1,274 patients in the insulin cohort were eligible for the 24-month analysis. During the study, 42.2% and 36.0% of patients from each cohort, respectively, had a significant treatment change. By 24 months, improved mean glycated hemoglobin (p < 0.001 for both cohorts) and reduced severity of several cardiovascular risk factors were observed in both cohorts; additionally, mean weight was reduced in the exenatide BID cohort (p < 0.001) and increased in the insulin cohort (p < 0.001). Hypoglycemia was reported by 18.4% of the exenatide BID cohort and 36.8% of the insulin cohort; 25.9% of the exenatide BID cohort and 10.0% of the insulin cohort had met the secondary endpoint of glycated hemoglobin <7.0%, no weight gain, and no hypoglycemia.
  
  
  CONCLUSIONS
  CHOICE provided data on exenatide BID and insulin usage patterns and 24-month outcomes in clinical practice. On average, improved glycemic control and reduced severity of cardiovascular risk factors were observed in both cohorts, and those in the exenatide BID cohort also had mean weight loss.
authors.affiliation: Department of Endocrinology, UZ Gasthuisberg, 3000, Leuven, Belgium, chantal.mathieu@uzleuven.be.
authors.forename: Chantal
authors.initials: C
authors.lastname: Mathieu
authors.forename: Claes-Göran
authors.initials: CG
authors.lastname: Ostenson
authors.forename: Stephan
authors.initials: S
authors.lastname: Matthaei
authors.forename: Matthew
authors.initials: M
authors.lastname: Reaney
authors.forename: Thure
authors.initials: T
authors.lastname: Krarup
authors.forename: Bruno
authors.initials: B
authors.lastname: Guerci
authors.forename: Jacek
authors.initials: J
authors.lastname: Kiljański
authors.forename: Carole
authors.initials: C
authors.lastname: Salaun-Martin
authors.forename: Hélène
authors.initials: H
authors.lastname: Sapin
authors.forename: Michael
authors.initials: M
authors.lastname: Theodorakis
references.citation: Diabetes Obes Metab. 2012 Jan;14(1):77-82
references.pmid: 21883806
references.citation: N Engl J Med. 2011 May 5;364(18):1685-7
references.pmid: 21542739
references.citation: Diabetologia. 2009 Oct;52(10):2046-55
references.pmid: 19688338
references.citation: Diabetes Ther. 2012 Nov;3(1):6
references.pmid: 22714818
references.citation: Health Technol Assess. 2010 Jul;14(36):1-248
references.pmid: 20646668
references.citation: Emerg Med J. 2003 Jan;20(1):54-60
references.pmid: 12533370
references.citation: Clin Ther. 2007 Nov;29(11):2333-48
references.pmid: 18158075
references.citation: Curr Med Res Opin. 2009 Mar;25(3):691-700
references.pmid: 19196223
references.citation: Lancet. 2010 Jun 26;375(9733):2234-43
references.pmid: 20609969
references.citation: Diabetes Care. 2005 May;28(5):1092-100
references.pmid: 15855572
references.citation: BMJ. 2012 Jun 12;344:e3987
references.pmid: 22692653
references.citation: J Biopharm Stat. 2007;17(1):1-13; discussion 15-7, 19-21, 23-7 passim
references.pmid: 17219753
references.citation: Diabetes Care. 2005 May;28(5):1083-91
references.pmid: 15855571
references.citation: Clin Ther. 2007;29 Spec No:1284-92
references.pmid: 18046928
references.citation: Diabetologia. 2012 Jun;55(6):1577-96
references.pmid: 22526604
references.citation: J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl A):1-22
references.pmid: 22313233
references.citation: Diabetes Care. 2004 Nov;27(11):2628-35
references.pmid: 15504997
references.citation: Diabetes Obes Metab. 2009 Dec;11(12):1122-30
references.pmid: 19930004
references.citation: Diabetologia. 2007 Feb;50(2):259-67
references.pmid: 17160407
references.citation: Lancet. 2012 Jun 16;379(9833):2270-8
references.pmid: 22683137
references.citation: Diabetes Res Clin Pract. 2011 Aug;93(2):e87-e91
references.pmid: 21636161
references.citation: Curr Med Res Opin. 2011 Mar;27(3):531-40
references.pmid: 21219119
references.citation: Ann Intern Med. 2005 Oct 18;143(8):559-69
references.pmid: 16230722
references.citation: Diabetes Ther. 2012 Nov;3(1):9
references.pmid: 22926918
references.citation: BMJ. 2000 Aug 12;321(7258):405-12
references.pmid: 10938048
references.citation: Health Aff (Millwood). 2010 Oct;29(10):1818-25
references.pmid: 20921481
references.citation: BMJ. 2012 Jun 12;344:e3974
references.pmid: 22692652
references.citation: N Engl J Med. 2007 Oct 25;357(17):1716-30
references.pmid: 17890232
references.citation: Curr Med Res Opin. 2011 Dec;27(12):2335-42
references.pmid: 22085180
references.citation: N Engl J Med. 2009 Oct 29;361(18):1736-47
references.pmid: 19850703